Printer Friendly

CEO INTERVIEW: EDWARD LEGERE - PEREGRINE PHARMACEUTICALS INC (PPHM).

(MAV608) EDWARD LEGERE - PEREGRINE PHARMACEUTICALS INC (PPHM). Describes the company's business and its background; prospects for the industry, with positive and negative trends; competitive threats; strategic opportunities for the firm including its marketing plans and acquisition potential; management strength and organization; and the financial prospects of the firm looking forward. Sector: Drug Delivery. Published date 8/6/01. Tickers featured: PPHM. Complete text approximately 3000 words. Document # MAV608.

CEO INTERVIEWS, The Wall Street Transcript, 67 Wall Street, NY 10005. Voice (212) 952 7433. Fax: (212) 668-9842. E-mail: transcript@twst.com.

***
COPYRIGHT 2001 Wall Street Transcript Corporation
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:CEO INTERVIEW: EDWARD LEGERE - PEREGRINE PHARMACEUTICALS INC (PPHM).
Publication:Wall Street Transcript Digest
Article Type:Brief Article
Geographic Code:1USA
Date:Aug 6, 2001
Words:90
Previous Article:CEO INTERVIEW: DAVID SOUTHWELL - SEPRACOR INC (SEPR).
Next Article:CEO INTERVIEW: REMI BARBIER - PAIN THERAPEUTICS INC (PTIE).
Topics:


Related Articles
STEPHEN GARDNER - PEREGRINE SYSTEMS INC (PRGN).
PEREGRINE INITIATES ANTIBODY GENERATION AGAINST 2 TARGETS.
Peregrine receives endothelial growth factor patents.
AFFITECH/PEREGRINE TO PRODUCE HUMAN TARGETING AGENT ANTIBODIES.
CEO INTERVIEW: STEVEN KING - PEREGRINE PHARMACEUTICALS INC (PPHM).
Peregrine Pharmaceuticals Awarded New United States Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters